bortezomib

You have access
Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER
TAKUYA IMATOH, TAICHI MATSUMOTO, YUTAKA HARAMAKI and KEISUKE MIGITA

Anticancer Research March 2023, 43 (3) 1341-1349; DOI: https://doi.org/10.21873/anticanres.16282
You have access
Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor
MASAKI YODA, KANAME SAKUMA, TOMOYUKI KII and AKIRA TANAKA

Anticancer Research September 2022, 42 (9) 4273-4283; DOI: https://doi.org/10.21873/anticanres.15927
You have access
Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells
KUNIHIRO ASANUMA, TOMOKI NAKAMURA, KOICHI NAKAMURA, TOMOHITO HAGI, TAKAYUKI OKAMOTO, KOUJI KITA, YUMI MATSUYAMA, KEISUKE YOSHIDA, YUMIKO ASANUMA and AKIHIRO SUDO

Anticancer Research September 2022, 42 (9) 4319-4328; DOI: https://doi.org/10.21873/anticanres.15932
You have access
Inhibition of Neurotoxicity/Anticancer Activity of Bortezomib by Caffeic Acid and Chlorogenic Acid
REONA MATSUDA, HIROSHI SAKAGAMI, SHIGERU AMANO, YOSUKE IIJIMA, MOTOHIKO SANO, YOSHIHIRO UESAWA, NOBUAKI TAMURA, YOHEI OISHI and HIROSHI TAKESHIMA

Anticancer Research February 2022, 42 (2) 781-790; DOI: https://doi.org/10.21873/anticanres.15536
You have access
Protection of Bortezomib-induced Neurotoxicity by Antioxidants
YOSUKE IIJIMA, KENJIRO BANDOW, SHIGERU AMANO, MOTOHIKO SANO, SHUNSUKE HINO, TAKAHIRO KANEKO, NORIO HORIE and HIROSHI SAKAGAMI

Anticancer Research July 2020, 40 (7) 3685-3696; DOI: https://doi.org/10.21873/anticanres.14357
You have access
Incorporating Bortezomib in the Management of Plasmablastic Lymphoma
ONYEDIKA UMEANAETO, JOSEPH GAMBOA, JESUS DIAZ, M. NAWAR HAKIM, JAVIER CORRAL, ALEXANDER PHILIPOVSKIY and SUMIT GAUR

Anticancer Research September 2019, 39 (9) 5003-5007; DOI: https://doi.org/10.21873/anticanres.13690
You have access
Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents
KYOUNG HA KIM, HEE-JEONG CHEONG, MIN YOUNG LEE, NAMSU LEE, KYU-TAEK LEE, SEONG KYU PARK and JONG-HO WON

Anticancer Research January 2019, 39 (1) 127-133; DOI: https://doi.org/10.21873/anticanres.13088
You have access
High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib
KANA OIWA, MIHOKO MORITA, SHINJI KISHI, MIYUKI OKURA, TOSHIKI TASAKI, YASUFUMI MATSUDA, KATSUNORI TAI, NAOKO HOSONO, TAKANORI UEDA and TAKAHIRO YAMAUCHI

Anticancer Research December 2016, 36 (12) 6655-6662;
You have access
Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors
NATALIA MORENO and KORNELIUS KERL

Anticancer Research August 2016, 36 (8) 3883-3887;
You have access
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
MICHAEL MIAN, MARTINA TINELLI, ELENA DE MARCH, GLORIA TURRI, VITTORIO MENEGHINI, NORBERT PESCOSTA, TAMARA BERNO, ALESSANDRA MARABESE, PATRIZIA MONDELLO, FRANCESCA PATRIARCA, GIOVANNI PIZZOLO, GIANPIETRO SEMENZATO, SERGIO CORTELAZZO and RENATO ZAMBELLO

Anticancer Research March 2016, 36 (3) 1059-1065;

Main menu

User menu

Search

bortezomib

Pages